Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDA label proofreading deficiencies still holding up approvals, OGD study finds.

Executive Summary

ANDA LABELING DEFICIENCIES: ONE-THIRD DUE TO PROOFREADING PROBLEMS, according to a 1994 study recently released by FDA. The report by the Office of Generic Drugs Labeling Review Branch contends that "improved proofreading, being familiar with the full range of references in the Code of Federal Regulations, and becoming familiar with the agency preferences will significantly reduce the number of labeling deficiencies cited in `not approvable' letters and greatly facilitate the review process."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027131

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel